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Depressive disorders are a major cause of disability, 
increasing the risk of premature mortality, decreasing 
quality of life, and creating a substantial burden on 
health systems.1–3 Different estimates show that these 
disorders could affect more than 300 million people 
worldwide.4–7 However, these estimates have high 
temporal and geo graphical variation, making a periodical 
assessment for each country or region necessary.
Multiple studies have been done in Europe with a focus 
on the assessment of the prevalence of depression.5,8,9 
These studies suggested that the prevalence of depression 
across Europe is between 5% and 10%, with potentially 
large differences between countries (eg, 10% in the UK 
and 7% in Germany).5,9 Furthermore, differences in 
prevalence over time within the same countries might 
exist.5,10 Despite the use of large and, in some cases, 
representative samples in these studies, their results are 
difficult to compare due to differences in the variables 
collected and the assessed populations. Although some 
studies have assessed multiple European countries, most 
of them do not cover the whole of Europe.5,9,10 Additionally, 
the use of diag nostic codes in some estimations could 
not pick up the full extent of the prevalence of depression, 
missing some cases, such as those with little access to 
health care.4,5,9 An updated assessment of the prevalence 
of depressive disorders, including a basic set of relevant 
covariates, covering most European coun tries, and using 
a valid, reliable, and well established instrument for the 
assessment of depression, is essen tial for monitoring 
and planning health resources and services, both at a 
European-wide and a country-specific level.11
Different demographic and socioeconomic factors, such 
as self-identified gender, age, and social deprivation, have 
been linked to the prevalence of depression.10,12–14 These 
factors vary widely within and across countries and could 
contribute to international variation in the prevalence of 
depres sion. In Europe, socioeconomic differences 
between countries are pro nounced. Addi tionally, geo-
graphi cal and sociopolitical factors might explain 
differences between countries in the prevalence of depres-
sion.15 An in-depth analysis of the current prevalence of 
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Summary
Background We aimed to estimate the prevalence of current depressive disorder in 27 European countries, and to 
explore differences in prevalence between European countries and by gender.
Methods In this population-based study, we analysed data from respondents living in 27 European countries who 
were included in the second wave of the European Health Interview Survey, collected between 2013 and 2015. We 
assessed the prevalence of current depressive disorder using the eight-item Patient Health Questionnaire (PHQ-8), 
with depressive disorder defined as a PHQ-8 score of 10 or higher. Prevalence estimates and 95% CIs were calculated 
for all 27 countries overall and for each country individually. We assessed variation in prevalence (country vs the rest 
of Europe) using crude and adjusted prevalence ratios obtained from negative binomial regression models. We did all 
analyses for the total sample and stratified by gender.
Findings Our analysis sample comprised 258 888 individuals, of whom 117 310 (weighted proportion 47·8%) were 
men and 141 578 (52·2%) were women. The overall prevalence of current depressive disorder was 6·38% (95% CI 
6·24–6·52) with important variation across countries, ranging from 2·58% (2·14–3·02) in the Czech Republic 
to 10·33% (9·33–11·32) in Iceland. Prevalence was higher in women (7·74% [7·53–7·95]) than in men (4·89% 
[4·71–5·08]), with clear gender differences for all countries except Finland and Croatia. Compared with the other 
European countries in our sample, those with the highest adjusted prevalence ratios were Germany (1·80 [1·71–1·89]) 
and Luxembourg (1·50 [1·35–1·66]), and those with the lowest adjusted prevalence ratios were Slovakia (0·28 
[0·24–0·33]) and the Czech Republic (0·32 [0·27–0·38]).
Interpretation Depressive disorders, although common across Europe, vary substantially in prevalence between 
countries. These results could be a baseline for monitoring the prevalence of current depressive disorder both at a 
country level in Europe and for planning health-care resources and services.
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depression from an inter-country (European-wide) and 
intra-country (countrywide) perspective, taking into 
account these factors, would provide crucial data that 
could be used to inform health policy for the prevention of 
depression at the European level, and might allow 
proposal of specific preventive measures adapted to the 
particularities of those countries where prevalence is 
higher relative to other countries.
We aimed to estimate the prevalence of current depres-
sive disorder in 27 European countries and assess differ-
ences between the prevalence for each specific country 
and that of the whole European sample.
Methods
Study design and population
In this population-level cross-sectional study, we used data 
from the second wave of the European Health Interview 
Survey (EHIS-2). The EHIS-2 is a European-wide survey, 
repre sentative at country level, which includes all 
27 EU member states plus the UK, Norway, Iceland, and 
Turkey.16,17 The target population of the surveys comprised 
indi viduals aged 15 years and older (16 years and older for 
Sweden and the UK) living in private households residing 
in the territory of the country at the time of the data 
collection. Depending on the country, the EHIS-2 sample 
was selected using different sampling methods (including 
single-stage and multiple-stage strategies) and data were 
collected from 2013 to 2015 through different pro cedures 
(postal, face-to-face, telephone, internet, or mixed 
methods). To maximise the response rate and minimise 
possible bias and differences in responses related to the 
method of data collection, interviews were done by trained 
interviewers. The non-response rate by country in EHIS-2, 
before substitutions (ie, use of reserve sample participants 
when main sample participants were non-contactable), 
ranged from 16% to 70%, and did not exceed 40% in 
17 of 27 countries.16 However, compensa tion methods for 
non-response rates were used to reach the estimated 
minimum effective sample size in those countries where 
this was not achieved.16 The overall ratio between the actual 
effective sample size and the estimated minimum effective 
sample size in the countries included in this study ranged 
from 0·81 (Greece) to 2·17 (Latvia).16 Additionally, the 
mixed sampling methods were accounted for in our 
analyses through weighting.16 More detailed information 
about the specific sampling methods, response rates, and 
how EHIS-2 determined the sample to achieve compar-
ability and represen tativeness can be found in the quality 
report and metho dological manual of EHIS-2.16,17
EHIS-2 anonymised microdata were provided by 
Eurostat after we signed an agreement about security, 
con fi dentiality, accessibility, and use of data. Ethical 
approval was not required for this research due to the 
public and anonymous nature of the data we used.
Data collection and analysis
The EHIS-2 questionnaire collects data on health status, 
socioeconomic status, mental health (including the 
eight-item Patient Health Questionnaire [PHQ-8]), and 
other determinants of health (eg, gender and age). 
Conceptual equivalence of all items across countries was 
ensured through appropriate modifications where 
Research in context
Evidence before this study
We searched PubMed without language restrictions for 
observational studies published from database inception until 
July 27, 2020, reporting prevalence estimates for any European 
country using population-wide or representative samples. 
We used the MeSH terms “depress*” AND “prevalence” AND 
“Europe” AND (“representative*” OR “population*”). Multiple 
studies have been done in European countries examining the 
prevalence of depression. Evidence from specific countries 
suggests differences between them and over time. 
Additionally, some studies suggested that these differences 
could be affected by variability between countries in 
sociodemographic, health-related, and lifestyle factors. Despite 
the use of large, population-wide, and, in some cases, 
representative samples in these studies, their results were 
difficult to compare due to differences in the measures used to 
assess depression, the type of variables considered, and the 
populations studied.
Added value of this study
To our knowledge, this is the first study to assess differences in 
the prevalence of current depressive disorder in Europe using 
primary representative data of the general population in the 
community at country level. Using data for 27 European 
countries collected between 2013 and 2015 as part of the 
second wave of the European Health Interview Survey, we 
found that the overall prevalence of current depressive disorder 
is high (6·38%), with important variation across European 
countries. The highest prevalence estimate for an individual 
country was approximately four times higher than the lowest 
estimate and the highest prevalences were seen in countries 
with high economic development. Additionally, we found that 
prevalence of depression was higher among women than 
among men, with a clear difference in prevalence according to 
gender in all countries except for Finland and Croatia.
Implications of all the available evidence
Our findings could be a reference and baseline for the 
monitoring of the prevalence of current depressive disorder, 
the planning of health-care resources and services, and the 
development of screening and other preventive strategies both 
at a European and country level. Moreover, our analyses might 
be considered a replicable approach to assessing and comparing 
prevalence of depression between European countries.
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needed (eg, wording modifications to adapt questions to 
the specificities of the national languages).
We assessed the prevalence of current depressive 
disorder using PHQ-8, an instrument based on Diagnostic 
and Statistical Manual of Mental Disorders (DSM) IV 
criteria, which has been shown to be valid and reliable for 
assessing current depressive disorder in the general 
population.18–21 Because of the absence of availability of 
PHQ-8 variables in the microdata files from Belgium, 
the Netherlands, and Spain,16 data from these countries 
were not included in this study. Additionally, because of 
the paucity of information about their qual ity,16 data from 
Turkey were also excluded. Hence, only 27 of 31 countries 
included in the EHIS-2 had available data on current 
depressive disorder and so were included in our analyses.
The PHQ-8 is a self-reported questionnaire composed 
of eight items, which correspond to the DSM-IV 
diagnostic criteria for major depressive episode 
excluding thoughts of death and suicide. The recall 
period corresponds to the previous 2 weeks and the 
response scale ranged from 0 (not at all) to 3 (nearly 
every day). The PHQ-8 score is calculated by adding the 
answers for each of the items and ranges from 0 to 24. 
Based on results from previous validation studies,19,21 for 
Total population (n=258 888) Men (n=117 310) Women (n=141 578)
Age group, years
15–29 19·89% (19·64–20·14) 20·79% (20·42–21·16) 19·06% (18·74–19·39)
30–44 24·81% (24·57–25·06) 25·35% (24·98–25·72) 24·32% (23·99–24·64)
45–59 25·79% (25·55–26·02) 26·31% (25·95–26·66) 25·31% (24·99–25·63)
60–74 19·60% (19·40–19·80) 19·09% (18·80–19·38) 20·06% (19·78–20·34)
≥75 9·91% (9·75–10·08) 8·46% (8·25–8·68) 11·25% (11·00–11·49)
Country of birth
Native born 91·87% (91·70–92·04) 92·26% (92·02–92·50) 91·50% (91·27–91·74)
Another EU member state 3·15% (3·05–3·26) 2·85% (2·70–3·00) 3·43% (3·28–3·58)
Non-EU country 4·98% (4·84–5·12) 4·89% (4·69–5·09) 5·07% (4·88–5·26)
Residence area population
Densely 36·06% (35·79–36·33) 35·20% (34·80–35·60) 36·85% (36·48–37·22)
Intermediate 33·05% (32·79–33·31) 33·25% (32·86–33·65) 32·86% (32·51–33·22)
Thinly 30·89% (30·64–31·14) 31·55% (31·18–31·92) 30·28% (29·95–30·62)
Net monthly income (quintiles)
1 (lower income) 19·29% (19·07–19·52) 17·57% (17·25–17·88) 20·88% (20·56–21·19)
2 19·44% (19·21–19·66) 18·13% (17·80–18·46) 20·63% (20·31–20·95)
3 19·80% (19·57–20·02) 19·46% (19·11–19·80) 20·11% (19·81–20·42)
4 20·44% (20·21–20·66) 21·49% (21·15–21·83) 19·48% (19·18–19·77)
5 (higher income) 21·03% (20·80–21·27) 23·36% (23·00–23·72) 18·90% (18·60–19·20)
Long-standing illness 42·61% (42·33–42·88) 39·72% (39·32–40·12) 45·26% (44·88–45·64)
General activity limitation
Severely limited 6·57% (6·44–6·71) 6·07% (5·88–6·26) 7·04% (6·84–7·23)
Limited but not severely 19·10% (18·89–19·32) 17·31% (17·01–17·60) 20·75% (20·45–21·05)
Not limited 74·32% (74·09–74·56) 76·63% (76·29–76·96) 72·21% (71·88–72·54)
Educational level
Primary or lower 9·66% (9·51–9·82) 8·38% (8·17–8·59) 10·84% (10·62–11·06)
Secondary 64·28% (64·01–64·55) 65·09% (64·69–65·49) 63·54% (63·18–63·90)
Tertiary 26·05% (25·80–26·31) 26·53% (26·15–26·91) 25·62% (25·29–25·95)
Body-mass index, kg/m²
<18·5 2·81% (2·71–2·91) 1·46% (1·35–1·57) 4·05% (3·89–4·21)
18·5–24·9 47·05% (46·77–47·33) 41·22% (40·81–41·63) 52·40% (52·01–52·78)
25–29·9 34·85% (34·58–35·13) 41·77% (41·36–41·63) 28·51% (28·17–28·85)
≥30 15·29% (15·09–15·49) 15·55% (15·25–15·85) 15·05% (14·78–15·32)
Diet (fruit and vegetables)
Daily 65·13% (64·87–65·40) 59·08% (58·68–59·49) 70·68% (70·34–71·02)
4–6 times per week 20·36% (20·14–20·59) 22·58% (22·24–22·93) 18·33% (18·04–18·61)
1–3 times per week 12·15% (11·97–12·33) 15·20% (14·91–15·49) 9·34% (9·13–9·56)
Less than once per week 2·36% (2·27–2·45) 3·14% (2·99–3·28) 1·65% (1·55–1·74)
(Table 1 continues on next page)
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this study we considered a PHQ-8 score of 10 or higher 
to be positive for current depressive disorder (sensitivity 
over 85% and specificity over 88%).19,21 Furthermore, the 
prevalence of depression was assessed using the scoring 
algorithm of PHQ-8 for major depressive syndrome 
and other depressive syndrome and a self-reported item 
(self-reported depression [SRD]; a single question on 
experiencing depression in the past 12 months:  “During 
the past 12 months, have you had depression? Yes/No”) 
were calculated as sensitivity analyses.17,18 Only interviews 
with complete information on depression using the 
PHQ-8 were included. Additionally, due to their known 
association with depression and usual inclusion in 
populational health studies, the following covariates 
were selected for the analyses: sociodemographic factors 
(gender, age, birthplace, degree of urbanisation of the 
individuals’ residence area, net monthly income of the 
household equivalised for each country, and educational 
level), health-related factors (long-standing illness and 
general activity limitation), and lifestyle factors (body-
mass index [BMI], intake of fruit and vegetables, 
smoking status, and physical activity [measured as 
number of days per week doing activities that cause at 
least a small increase in breathing or heart rate for at 
least 10 min continuously]).
Statistical analysis
We calculated the prevalence and 95% CI for current 
depressive disorder for each specific country and across 
all the included countries. Additionally, in a supple-
mentary analysis, we calculated the distribution by 
country of the scores for each PHQ-8 item (dichotomous: 
0 = item score of <2; 1 = item score of ≥2). To assess 
differences in the prevalence of current depressive 
disorder between each specific country and the rest of the 
included countries, we calculated the crude preva lence 
ratio from a bivariable negative binomial regres-
sion model and we calculated the adjusted prevalence 
ratio from a multivariable negative binomial regression 
model. To assess differences in prevalence, we adjusted 
the negative binomial model each country using a 
dummy variable (country vs the rest of Europe as 
reference) as the main explanatory factor. Because of 
their known association with depression, we included all 
covariates in the multivariable models using a theory-
driven approach (ie, an approach based on previous 
evidence and clinical relevance). We assessed the absence 
of multicollinearity by calculating the variance inflation 
factor for each of the multivariable models. We used the 
Wald test to assess the statistical significance of the 
variable country within the models. We did all analyses 
for the whole population and stratified by gender. In all 
our analyses, we took into account the final individual 
weights derived from the sampling strategy for each 
country (using the Taylor linearisation method for survey 
data to be as conserva tive as possible in the estimations). 
Moreover, because the population analysed was calcu-
lated by sum ming the populations of each country and 
expanded using individual weights, the use of final 
individual weights allowed us to compare estimates 
between each country and the rest of the included 
countries. The proportion of missing data for the 
variables in the study population ranged from 0% to 5·3% 
for household income from an open question and multi-
variable normality could not be assumed. To deal with 
missing data, we did multiple imputation using chained 
equa tions with five impu tations.22 Finally, we did 
sensitivity analyses calculating the prevalence and 
prevalence ratios (country vs all other included countries) 
using the algorithm scor ing of PHQ-8, the SRD indicator, 
and geographically pooled data.
We did all analyses using Stata version 16.1.
Total population (n=258 888) Men (n=117 310) Women (n=141 578)
(Continued from previous page)
Smoking status
Daily smoking 18·92% (18·70–19·14) 22·82% (22·48–23·16) 15·33% (15·06–15·61)
Occasional smoking 5·02% (4·89–5·14) 5·83% (5·63–6·02) 4·27% (4·12–4·42)
No smoking 76·07% (75·86–76·31) 71·35% (70·98–71·72) 80·40% (80·09–80·70)
Days per week physically active
0 55·43% (55·14–55·72) 53·22% (52·80–53·64) 57·46% (57·08–57·85)
1 9·01% (8·83–9·18) 8·93% (8·67–9·19) 9·08% (8·84–9·32)
2 11·50% (11·31–11·69) 11·44% (11·16–11·72) 11·55% (11·30–11·81)
3 9·58% (9·40–9·75) 10·18% (9·91–10·44) 9·03% (8·80–9·25)
4 4·48% (4·36–4·60) 5·14% (4·95–5·33) 3·87% (3·72–4·02)
5 3·78% (3·67–3·90) 4·29% (4·11–4·48) 3·31% (3·17–3·45)
6 1·62% (1·55–1·70) 2·01% (1·88–2·14) 1·27% (1·18–1·35)
7 4·60% (4·49–4·73) 4·80% (4·62–4·98) 4·43% (4·27–4·59)
Data are weighted proportion with 95% CI in parentheses.
Table 1: General characteristics of the study population overall and by gender
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Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results
316 333 individuals were in the EHIS-2 dataset, of whom 
39 608 were excluded because they were not in the 
countries included in our analysis and 17 837 were 
excluded because they did not meet the inclusion criteria. 
Our final analysis sample comprised 258 888 respon-
dents to the EHIS-2 (117 310 [weighted proportion 47·8%] 
men and 141 578 [52·2%] women) who completed the 
PHQ-8 (table 1). The prevalence of current depressive 
disorder for our European cohort was 6·38% (95% CI 
6·24–6·52) overall, 4·89% (4·71–5·08) for men, and 
7·74% (7·53–7·95) for women (table 2). The subgroups 
with the highest prevalence of current depressive 
disorder were generally those who were older (aged 
≥75 years), born in a non-EU country, living in densely 
populated areas, had a long-standing illness, were 
severely limited in their activity, had a BMI of 30 kg/m² 
or more or 18·5 kg/m² or less, were daily smokers, and 
were sedentary (table 2). Additionally, the prevalence of 
depression decreased as income and educational level 
increased and as fruit and vegetable consumption 
decreased in the total population. These patterns were 
consistent in both genders (table 2).
The prevalence of current depressive disorder by 
country ranged from 2·56% (95% CI 2·16–2·97) in 
Slovakia to 10·33% (9·33–11·32) in Iceland (table 3). 
Prevalence was higher among women than among men, 
both overall and in all countries, with clear gender 
differences seen in prevalence for all countries except for 
Finland (4·86% [3·88–5·83] for men and 5·59% 
[4·70–6·48] for women) and Croatia (3·08% [2·40–3·76] 
for men and 3·38% [2·71–4·05] for women). Gender 
differences in the prevalence of current depressive 
disorder were particularly prominent in Iceland and 
Portugal, with the prevalence being twice as high in 
women than in men. A sensitivity analysis using the 
algorithm scoring for the PHQ-8 and the SRD indicator 
showed slightly higher but consistent prevalence 
estimates compared with using a PHQ-8 cutoff score of 10 
or higher (appendix p 2) Additionally, we calculated the 
distribution of scores for each PHQ-8 item by country, 
and found that, overall, the item with the highest 
prevalence of positives was item 4 (ie, feeling tired or 
having little energy; 11·90% [11·72–12·08]) and the item 
with the lowest prevalence was item 8 (ie, moving or 
speaking so slowly that other people could have noticed? 
Or the opposite—being so fidgety or restless that you 
have been moving around a lot more than usual; 2·56% 
[2·47–2·65]; appendix p 3).
In all countries, the crude prevalence ratio of current 
depressive disorder varied significantly when compared 
with the rest of the European population, except for 
Bulgaria and Estonia (figure). In adjusted analyses, 
Bulgaria, Norway, and Romania were the only countries 
that did not significantly differ from the European average 
(figure). After adjustment for covariates, all countries 
with significantly high crude prevalence ratios remained 
significantly increased, whereas the adjusted prevalence 
ratio for Estonia was significantly reduced compared 







Overall 6·38% (6·24–6·52) 4·89% (4·71–5·08) 7·74% (7·53–7·95)
Age group, years
15–29 5·26% (4·93–5·59) 3·63% (3·22–4·04) 6·89% (6·37–7·40)
30–44 4·86% (4·59–5·12) 4·21% (3·83–4·59) 5·48% (5·11–5·84)
45–59 7·10% (6·82–7·39) 5·69% (5·31–6·07) 8·45% (8·03–8·87)
60–74 5·85% (5·58–6·12) 4·65% (4·30–4·99) 6·90% (6·50–7·30)
≥75 11·59% (11·01–12·16) 8·11% (7·38–8·84) 13·99% (13·16–14·81)
Country of birth
Native born 6·26% (6·12–6·41) 4·78% (4·59–4·98) 7·63% (7·41–7·84)
Another EU member 
state 
6·41% (5·55–7·26) 5·07% (3·86–6·29) 7·43% (6·25–8·60)
Non-EU country 8·53% (7·73–9·32) 6·85% (5·79–7·92) 10·01% (8·83–11·18)
Residence area population
Densely 6·95% (6·69–7·21) 5·54% (5·20–5·89) 8·18% (7·81–8·55)
Intermediate 6·16% (5·92–6·41) 4·73% (4·41–5·06) 7·49% (7·12–7·85)
Thinly 5·94% (5·72–6·17) 4·33% (4·05–4·62) 7·48% (7·13–7·83)
Net monthly income (quintiles)
1 (lower income) 10·62% (10·20–11·04) 9·22% (8·60–9·84) 11·70% (11·13–12·28)
2 7·68% (7·33–8·03) 5·88% (5·41–6·35) 9·13% (8·62–9·64)
3 5·99% (5·69–6·30) 4·45% (4·06–4·85) 7·36% (6·90–7·82)
4 4·67% (4·39–4·95) 3·60% (3·25–3·96) 5·76% (5·34–6·18)
5 (higher income) 3·31% (3·08–3·53) 2·43% (2·15–2·72) 4·30% (3·92–4·67)
Long-standing illness
Yes 11·80% (11·52–12·08) 9·69% (9·29–10·08) 13·50% (13·10–13·89)
No 2·35% (2·23–2·48) 1·74% (1·58–1·89) 2·98% (2·79–3·17)
General activity limitation
Severely limited 34·58% (33·55–35·61) 30·60% (29·09–32·12) 37·72% (36·33–39·12)
Limited but not severely 10·97% (10·57–11·37) 8·85% (8·28–9·43) 12·59% (12·04–13·14)
Not limited 2·70% (2·59–2·82) 1·96% (1·81–2·11) 3·42% (3·25–3·60)
Educational level
Primary or lower 11·48% (10·93–12·02) 8·07% (7·33–8·80) 13·90% (13·14–14·66)
Secondary 6·52% (6·34–6·70) 5·11% (4·88–5·35) 7·84% (7·57–8·11)
Tertiary 4·13% (3·90–4·37) 3·35% (3·03–3·67) 4·88% (4·54–5·21)
Body-mass index, kg/m²
<18·5 9·09% (8·00–10·17) 7·90% (6·03–9·76) 9·48% (8·17–10·79)
18·5–24·9 5·49% (5·29–5·69) 4·41% (4·13–4·70) 6·26% (6·00–6·53)
25–29·9 5·73% (5·51–5·95) 4·21% (3·95–4·47) 7·77% (7·39–8·16)
≥30 10·10% (9·65–10·55) 7·72% (7·13–8·32) 12·35% (11·68–13·02)
Diet (fruit and vegetables)
Daily 5·60% (5·43–5·76) 3·96% (3·74–4·17) 6·85% (6·61–7·09)
4–6 times per week 6·24% (5·93–6·55) 4·54% (4·15–4·92) 8·17% (7·67–8·67)
1–3 times per week 9·06% (8·58–9·54) 7·43% (6·85–8·02) 11·48% (10·67–12·29)
Less than once per week 15·34% (13·96–16·71) 12·79% (11·08–14·51) 19·77% (17·47–22·07)
(Table 2 continues on next page)
See Online for appendix
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with the highest adjusted prevalence ratios compared 
with the rest of Europe were Germany (1·80 [1·71–1·89]) 
and Luxembourg (1·50 [1·35–1·66]) and the countries 
with the lowest adjusted prevalence ratios were Slovakia 
(0·28 [0·24–0·33]) and the Czech Republic (0·32 
[0·27–0·38]; appendix p 4). In sensitivity analyses, the 
crude and adjusted prevalence ratio estimates for each 
country calculated using the algorithm scoring method 
for the PHQ-8 and the SRD indicator were consistent 
with those obtained using the PHQ-8 cutoff score of 
10 or higher in most of countries and, particularly, in 
countries with the highest and lowest adjusted 
prevalence ratios (appendix p 5). Additionally, sensitivity 
analyses using geographically pooled data showed that 
the geographical distribution of countries might have 
influ enced the prevalences estimated in our main 
analyses, with countries in western Europe having a 
significantly higher prevalence of current depressive 
disorder than countries in the other regions of Europe 
(appendix p 6). Among men, the highest prevalence 
ratios compared with the rest of Europe were in Germany 
and Ireland and the lowest prevalence ratios were in the 
Czech Republic and Slovakia (table 4). Among women, 
the highest prevalence ratios compared with the rest of 
Europe were in Germany and Luxembourg and the 
lowest prevalence ratios were in Slovakia and the 
Czech Republic (table 4).
Discussion
To our knowledge, this study is one of the largest to 
specifically focus on comparing the prevalence of current 
depressive disorder by country in Europe that has included 
most countries and has used primary repre senta tive data 
of the general popu lation in the community. We found 
that the overall prevalence of current depressive disorder 
in Europe is high (6·38%), with important variation across 
countries (ranging from 2·58% in the Czech Republic to 
10·33% in Iceland). Prevalence was substantially higher 
among women than among men in all countries except 
Finland and Croatia. These results could be used as a 
base line for further studies on the prevalence of current 
depressive disorder in Europe and to identify determinants 
for the observed cross-national variation.
Differences in the prevalence of depression have been 
observed in previous studies overall for the whole of 
Europe and by country.4,9 Our estimates are lower than 
those of a previous meta-analysis by Lim and colleagues9 
that reported an overall prevalence for the whole of Europe 
of 11·9%, but higher than WHO estimates of an overall 
prevalence of 4·2% for the European region.4 Notably, 
differences in the operational measure of depression 
between these previous reports and our study could be 
relevant to understand the variations found. Although we 
focused on current depressive disorder assessed via the 
PHQ-8, Lim and colleagues’ meta-analysis used a wider 
definition of depression (ie, depressive symptoms using 
validated diagnostic or self-report instruments).9 Inclusion 
of individuals who do not meet the criteria for a diagnosis 
of major depression (eg, caused by bereavement, medical 
conditions, or substance use) or who have subclinical 
depression (eg, without functional impairment) might 
have led to an overestimation of prevalence in this meta-
analysis. This potential over estimation was also suggested 
by the results of our sensitivity analysis using the 
SRD indicator, which provided a wider definition of both 
depression and temporal timeframe. By contrast, the 
WHO report4 used a narrower definition of depression 
based on International Classification of Diseases and DSM 
diagnostic codes. The loss of clinical cases through use of 
differing definitions is in general particularly problematic 
in prevalence studies, but the use of diagnostic codes 
specifically might lead to an under estimation of prevalence 
due to the possible exclusion of individuals with clinically 
relevant depression who have not received a diagnosis 
(eg, those without access to health services). Therefore, 
despite the potential cross-cultural differences between 
countries, because the operational measure of current 
depressive disorder used in our study is based on 
DSM criteria and also includes individuals with depression 
who might not have received a clinical diagnosis, our 
estimates could be considered to be a balanced and suitable 
estimation of the prevalence of current depressive disorder 
in Europe. These estimates could be used as a reference 
for the monitoring of the prevalence of depression in 
Europe. Additionally, they could provide a baseline for 
future epidemiological studies to determine at-risk groups 
that would support further research into determinants of 
health inequalities.
Our results show high variability in the prevalence of 
current depressive disorder between countries. Notably, 
Total population 
(n=15 757)
Men (n=5305) Women (n=10 452)
(Continued from previous page)
Smoking status
Daily smoking 8·31% (7·93–8·69) 6·30% (5·85–6·75) 11·05% (10·40–11·70)
Occasional smoking 6·18% (5·54–6·82) 5·22% (4·38–6·05) 7·38% (6·39–8·38)
No smoking 5·91% (5·76–6·07) 4·42% (4·21–4·62) 7·13% (6·90–7·35)
Days per week physically active
0 7·86% (7·66–8·07) 6·27% (5·99–6·55) 9·22% (8·92–9·51)
1 5·02% (4·57–5·47) 3·59% (3·03–4·16) 6·31% (5·62–7·00)
2 4·41% (4·04–4·78) 3·03% (2·56–3·50) 5·66% (5·10–6·21)
3 4·34% (3·92–4·76) 3·51% (2·95–4·06) 5·20% (4·55–5·84)
4 4·17% (3·55–4·80) 3·22% (2·46–3·98) 5·33% (4·31–6·35)
5 4·05% (3·48–4·63) 2·61% (1·95–3·27) 5·77% (4·78–6·75)
6 4·48% (3·43–5·53) 3·18% (1·88–4·47) 6·37% (4·63–8·11)
7 5·07% (4·48–5·67) 4·02% (3·25–4·79) 6·12% (5·21–7·02)
Data are for all respondents with current depressive disorder, defined as a PHQ-8 score of 10 or higher. Data are 
weighted percentage with 95% CI in parentheses. EU member states include the 28 members states as of  2015. 
PHQ-8=eight item Patient Health Questionnaire. 
Table 2: Prevalence of current depressive disorder by demographic and clinical characteristics, overall and 
by sex 
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based on the results of previous prevalence studies,5,6,15 
some of the higher prevalences of depression were 
found in countries where we expected to find lower-
than-average prevalences (eg, Iceland or Germany), and 
we found lower prevalences of depression in some 
countries where we expected to find higher-than-average 
prevalences (eg, Czech Republic or Lithuania). Although 
the summary estimates given for Europe hide between-
country heterogeneity, both our geographically clustered 
analyses and previous research suggest that western 
European countries have a higher prevalence of 
depression.9,13 Additionally, the small differ ence between 
crude and adjusted prevalence ratios in most of countries 
suggests that individual factors might have a small 
influence on the prevalence of current depressive 
disorder. Even though particular caution is needed in 
interpreting the results of geographically pooled clusters, 
both our findings and previous research suggest that 
demographic, cultural, and sociopolitical factors (eg, the 
variability between countries in population ageing, 
health-care access, work–life balance, job insecurity, 
and the increase of living costs) might be relevant 
determinants of the observed differences.9,13,15,23,24 These 
factors might have greater influence on the prevalence 
of current depres sive disorders in countries with higher 
socioeconomic development (eg, Iceland or Germany) 
than in countries with moderate or lower socio-
economic development (eg, Czech Republic or 
Slovakia).9,23 There fore, the adoption of public health 
policies to try to minimise the effect of these factors 
on health (eg, through universal health coverage that 
adequately resources mental health care and public 
health preventive interventions) might reduce the 
prevalence of depression, especially in countries with 
higher prevalences of current depressive disorder and 
economic develop ment.10,13,23 Neverthe less, further 
research including all European countries that considers 
both country-level and individual-level socioeconomic 
factors (including cultural and sociopoli tical factors) 
could help us to better understand factors related to the 
prevalence of depression.
In terms of gender differences in current depressive 
disorder, clear differences in prevalence were found in all 
countries except Finland and Croatia. These results are in 
Total population (n=258 888) Men (n=117 310) Women (n=141 578)
n Prevalence (95% CI) n Prevalence (95% CI) n Prevalence (95% CI)
Austria 15 701 4·29% (3·82–4·77) 6953 3·41% (2·71–4·12) 8748 5·13% (4·49–5·78)
Bulgaria 5258 6·53% (5·88–7·19) 2458 4·90% (4·07–5·73) 2800 7·99% (7·00–8·98)
Croatia 5016 3·24% (2·76–3·72) 2350 3·08% (2·40–3·76) 2666 3·38% (2·71–4·05)
Cyprus 4695 3·31% (2·80–3·83) 2216 2·48% (1·84–3·13) 2479 4·06% (3·27–4·85)
Czech Republic 6607 2·58% (2·14–3·02) 2776 1·71% (1·17–2·25) 3831 3·39% (2·71–4·07)
Denmark 5449 7·17% (6·45–7·89) 2489 4·88% (3·99–5·78) 2960 9·43% (8·31–10·54)
Estonia 5439 6·64% (5·95–7·34) 2310 4·73% (3·81–5·65) 3129 8·26% (7·25–9·28)
Finland 5146 5·23% (4·58–5·89) 2210 4·86% (3·88–5·83) 2936 5·59% (4·70–6·48)
France 14 191 7·03% (6·54–7·51) 6843 4·78% (4·20–5·35) 7348 9·12% (8·35–9·89)
Germany 24 404 9·24% (8·82–9·66) 11 084 7·69% (7·12–8·27) 13 320 10·73% (10·13–11·34)
Greece 7834 3·39% (2·92–3·85) 3216 2·57% (1·90–3·23) 4618 4·13% (3·48–4·77)
Hungary 5777 7·98% (7·26–8·69) 2678 5·89% (4·97–6·81) 3099 9·82% (8·76–10·88)
Iceland 3812 10·33% (9·33–11·32) 1872 6·67% (5·48–7·86) 1940 14·02% (12·43–15·61)
Ireland 9046 7·67% (6·89–8·44) 4078 6·50% (5·45–7·54) 4968 8·80% (7·66–9·93)
Italy 21 934 3·81% (3·55–4·07) 10 358 2·62% (2·30–2·94) 11 576 4·88% (4·48–5·29)
Latvia 6607 4·61% (4·08–5·13) 2692 2·97% (2·31–3·63) 3915 5·90% (5·11–6·68)
Lithuania 4982 3·01% (2·56–3·46) 1956 1·75% (1·20–2·30) 3026 4·05% (3·37–4·73)
Luxembourg 3629 9·74% (8·76–10·72) 1657 8·12% (6·77–9·46) 1972 11·34% (9·91–12·76)
Malta 3974 3·27% (2·69–3·84) 1899 2·16% (1·49–2·84) 2075 4·38% (3·45–5·30)
Norway 8069 5·21% (4·62–5·79) 4059 4·01% (3·29–4·73) 4010 6·41% (5·49–7·33)
Poland 22 076 4·31% (4·01–4·62) 9620 3·18% (2·79–3·57) 12 456 5·29% (4·83–5·74)
Portugal 17 974 9·15% (8·54–9·77) 7850 4·54% (3·91–5·18) 10 124 13·24% (12·24–14·23)
Romania 16 422 4·38% (4·04–4·72) 7768 3·82% (3·36–4·27) 8654 4·91% (4·41–5·40)
Slovakia 5489 2·56% (2·16–2·97) 2454 1·84% (1·32–2·36) 3035 3·24% (2·62–3·85)
Slovenia 5914 5·50% (4·89–6·12) 2653 3·84% (3·05–4·63) 3261 7·12% (6·17–8·06)
Sweden 5737 8·75% (7·98–9·51) 3024 6·46% (5·56–7·36) 2713 11·08% (9·85–12·31)
UK 17 706 7·40% (6·90–7·89) 7787 6·08% (5·41–6·76) 9919 8·53% (7·81–9·25)
Data are number of respondents without weighting and weighted prevalence with 95% CI in parentheses. 
Table 3: Prevalence of current depressive disorder in 27 European countries, overall and by gender
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line with previous research,11,14 particularly with the 
findings of a study based on European Social Survey (ESS) 
data by Huijts and colleagues.15 The results of Huijts and 
colleagues’ study, which were stratified by gender, reported 
a higher overall prevalence of depressive symptoms using 
the Center for Epidemi ological Studies-Depression scale 
(10·2% for men and 18·8% for women) than we report 
here, and they also showed that Finland had a smaller 
difference in prevalence between men and women than 
we identified here (6·7% men and 8·2% women).15 
However, as was pointed out by Huijts and colleagues,15 
although the prevalence was considered, cross-country 
comparisons were not done. Accordingly, because we 
identified countries with particularly high prevalences of 
current depressive dis order, our results might provide a 
reference for cross-country comparisons of the prevalence 
of current depres sive disorder by gender in Europe, or a 
baseline for subsequent waves of EHIS and the ESS.
Our study had several limitations. First, data collection 
for EHIS-2 ended in 2015 and the contextual differences 
between countries in Europe could have since changed. 
Furthermore, different sampling methods were used to 
retrieve the information over a period of 3 years. Despite 
the delay between data collection and our analysis, our 
study is, to our knowledge, the most recent study based on 
primary data and covering the most EU countries. 
Therefore, our results could be a baseline for future 
comparisons at European-wide and country-wide levels 
using both subsequent waves of EHIS and other data. 
A further limitation relates to the use of the PHQ-8 to 
measure current depressive disorder rather than a clinical 
diagnostic interview, such as the Structured Clinical 
Interview for DSM or the The Composite International 
Diagnostic Interview. Additionally, different data collection 
methods were used across countries, although we had 
good com parability of the data and indicators from EHIS-2 
between countries. We are aware that the PHQ-8 does not 
have perfect sensitivity and specificity to detect current 
depressive disorder,19,21 but use of a cutoff score of 10 or 
higher on the PHQ-8 has previously been shown to have 
acceptable values when compared with these other 
instruments and also with other scoring methods (eg, the 
algorithm scoring method).19–21,25 Moreover, the PHQ-8 is 
based on DSM criteria for depression and its balance of 
feasibility and accuracy makes it a useful general popu-
lation indicator when using different data collection 
methods.26 Addi tionally, PHQ has been included in health 
surveys and medical records outside of Europe, potentially 
allowing worldwide comparisons, such as with the USA.27,28 
Nevertheless, given its metric properties, new studies to 
determine cutoff scores with higher sensitivity and 
specificity at population level could further increase the 
value of this tool. Another limitation is the high non-
response rate between different countries, including some 
of those with the highest over all adjusted prevalence ratio.16 
However, EHIS-2 used compensation methods for non-
response rates to enable them to reach suitable ratios 
Figure: Crude prevalence ratios (A) and adjusted prevalence ratios (B) for current depressive disorder (country 
vs the rest of Europe)
Datapoints are prevalence ratio with whiskers showing 95% CIs. Adjusted prevalence ratio is adjusted for gender,  
age, country of birth, residence area, net monthly income of the household (equivalised for the different 
countries), long-standing illness, general activity limitation educational level, body-mass index, diet (fruits and 
vegetables consumption), smoking status, and days per week being physically active. Crude adjusted prevalence 
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between the effective sample sizes and the minimum 
effective sample sizes.16 There fore, although the estimates 
for these countries must be considered carefully, the 
potential non-response bias could be considered to be at 
least partially controlled. Additionally, individuals not 
living in private households are not captured in EHIS-2, 
which might have affected the representativeness of the 
study. Due to the higher rates of mental disorders among 
people not living in private households, such as those in 
prison or living in care homes, their exclusion could have 
led to an underestimation of the prevalence of current 
depressive disorder. However, because these populations 
comprise a small proportion of the European population, 
our results could be considered valid for most of the 
general population in the 27 included European countries. 
Additionally, the use of the Taylor linearisation method 
could lead to conserva tive estima tions.29 Despite this 
potential limitation, because we aimed to compare 
prevalence between coun tries, and due to the potential 
implications that this com parison could have, we decided 
to go ahead with this method. Finally, some potentially 
relevant variables (eg, ethnicity or family history of 
depression) are not included in EHIS-2 and so we could 
not take them into account in our analyses. However, the 
covariates we did consider are usually included in all health 
surveys, allowing for comparison of results from different 
surveys.13,16 There fore, our analyses might be considered a 
valid and replicable approach to compare the prevalence of 
current depressive disorder between European countries.
In summary, we found that the overall prevalence of 
current depressive disorder in Europe is high, particularly 
among women, and that it varies widely between 
European countries, with an approximately four times 
difference in prevalence between the lowest-ranked and 
highest-ranked countries and with the greatest prevalences 
seen in countries with high economic development. These 
results could be used as a reference and baseline for the 
monitoring of the prevalence of current depressive 
disorder and highlight the need for the development 
of screening and preventive strategies for depression 
Men (n=117 310) Women (n=141 578)
Crude model Full adjusted model Crude model Full adjusted model
Austria 0·69 (0·56–0·86) 0·74 (0·60–0·91) 0·66 (0·58–0·75) 0·65 (0·57–0·74)
Bulgaria 1·00 (0·84–1·19) 0·93 (0·83–1·14) 1·03 (0·91–1·17) 1·06 (0·94–1·19)
Croatia 0·63 (0·50–0·79) 0·52 (0·42–0·65) 0·43 (0·36–0·53) 0·36 (0·30–0·44)
Cyprus 0·51 (0·39–0·66) 0·46 (0·36–0·58) 0·52 (0·43–0·64) 0·47 (0·39–0·56)
Czech Republic 0·34 (0·25–0·47) 0·26 (0·19–0·36) 0·43 (0·35–0·53) 0·35 (0·29–0·43)
Denmark 1·00 (0·83–1·20) 0·94 (0·79–1·13) 1·22 (1·08–1·38) 1·29 (1·14–1·45)
Estonia 0·97 (0·79–1·18) 0·63 (0·52–0·77) 1·07 (0·94–1·21) 0·75 (0·67–0·84)
Germany 1·85 (1·70–2·02) 1·88 (1·72–2·05) 1·54 (1·44–1·64) 1·74 (1·63–1·86)
Greece 0·52 (0·40–0·67) 0·44 (0·35–0·57) 0·53 (0·45–0·62) 0·41 (0·35–0·47)
Finland 0·99 (0·81–1·22) 0·89 (0·73–1·07) 0·72 (0·61–0·85) 0·77 (0·66–0·89)
France 0·97 (0·86–1·10) 0·98 (0·87–1·11) 1·21 (1·11–1·33) 1·20 (1·11–1·31)
Hungary 1·21 (1·03–1·42) 1·07 (0·93–1·24) 1·28 (1·14–1·43) 1·12 (1·01–1·24)
Iceland 1·36 (1·14–1·64) 1·19 (0·99–1·43) 1·81 (1·61–2·04) 1·42 (1·27–1·58)
Ireland 1·33 (1·13–1·57) 1·68 (1·38–1·88) 1·14 (1·00–1·30) 1·34 (1·19–1·52)
Italy 0·50 (0·44–0·57) 0·65 (0·57–0·73) 0·60 (0·55–0·65) 0·68 (0·63–0·74)
Latvia 0·61 (0·48–0·76) 0·46 (0·37–0·57) 0·76 (0·66–0·87) 0·55 (0·49–0·63)
Lithuania 0·36 (0·26–0·49) 0·35 (0·26–0·47) 0·52 (0·44–0·62) 0·45 (0·39–0·53)
Luxembourg 1·66 (1·40–1·97) 1·54 (1·28–1·84) 1·47 (1·29–1·67) 1·46 (1·28–1·66)
Malta 0·44 (0·32–0·61) 0·44 (0·32–0·61) 0·57 (0·46–0·70) 0·52 (0·42–0·64)
Norway 0·82 (0·68–0·98) 1·06 (0·89–1·26) 0·83 (0·71–0·96) 0·95 (0·83–1·10)
Poland 0·63 (0·55–0·72) 0·61 (0·54–0·69) 0·66 (0·61–0·72) 0·65 (0·59–0·71)
Portugal 0·93 (0·80–1·07) 0·87 (0·75–1·01) 1·74 (1·61–1·89) 1·40 (1·28–1·51)
Romania 0·77 (0·68–0·87) 1·13 (1·00–1·29) 0·62 (0·56–0·69) 0·85 (0·76–0·94)
Slovakia 0·37 (0·28–0·50) 0·26 (0·20–0·34) 0·41 (0·34–0·50) 0·31 (0·25–0·37)
Slovenia 0·78 (0·63–0·97) 0·78 (0·64–0·96) 0·92 (0·80–1·05) 0·90 (0·79–1·03)
Sweden 1·33 (1·15–1·54) 1·36 (1·19–1·56) 1·44 (1·29–1·62) 1·31 (1·18–1·47)
UK 1·29 (1·15–1·45) 1·16 (1·03–1·29) 1·12 (1·02–1·22) 1·07 (0·98–1·16)
Data are crude prevalence ratio or adjusted prevalence ratio, with 95% CI in parentheses. The adjusted prevalence ratio is adjusted for gender, age, country of birth, residence 
area, net monthly income of the household (equivalised for the different countries), long-standing illness, general activity limitation educational level, body-mass index, diet 
(fruits and vegetables consumption), smoking status, and days per week being physically active. All models were significant in relation to their respective null model 
(p<0·001).
Table 4: Prevalence ratio of current depressive disorder (country vs the rest of the European cohort) in 27 European countries, by gender 
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focused on the countries identified as having the highest 
prevalence and identified associated factors.
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